imported>Augmented Seventh: Reverted 1 edit by 74.194.217.93 (talk): Unsourced leadership change

2025-02-21T18:41:14Z

Reverted 1 edit by 74.194.217.93 (talk): Unsourced leadership change

New page

{{Short description|American protein engineering company}}
{{Undisclosed paid|date=August 2021}}
{{Infobox company
| name = Codexis, Inc.
| logo = Codexis.svg
| logo_size =
| logo_alt = Codexis
| type = [[Public company|Public]]
| traded_as = {{NASDAQ|CDXS}}<br />[[Russell 2000 Index|Russell 2000 Component]]
| industry = [[Protein engineering]], [[biocatalysis]], [[industrial enzymes]], [[fine chemicals]]
| foundation = {{start date and age|2002}}
| location = [[Redwood City, California]], U.S.
| key_people = {{unbulleted list|Stephen Dilly, Ph.D. ([[Chief Executive Officer|CEO]] and [[President (corporate title)|president]])|Ross Taylor ([[Chief Financial Officer|CFO]])}}
| revenue = {{profit}} [[United States Dollar|US$]]68.5 million <small>(''FY 2019'')</small>
| num_employees = 165 (as of April 2020)<ref>{{cite web |url=http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9ODU3NDF8Q2hpbGRJRD0tMXxUeXBlPTM=&t=1|title=Codexis Overview |accessdate=2011-04-03}}</ref>
| homepage = {{URL|codexis.com}}
}}

'''Codexis, Inc.''' is a protein engineering company that develops enzymes for pharmaceutical, food and medical applications.<ref>{{Cite web|title=Codexis, Molecular Assemblies Ink Enzyme Engineering Collaboration Agreement|url=https://www.genomeweb.com/business-news/codexis-molecular-assemblies-ink-enzyme-engineering-collaboration-agreement|access-date=2021-03-12|website=GenomeWeb|date=23 June 2020|language=en-us}}</ref><ref name=":0">{{Cite web|last=Hyde|first=Embriette|date=2019-09-04|title=Engineering the future of biotherapeutics|url=https://synbiobeta.com/engineering-the-future-of-biotherapeutics/|access-date=2021-03-12|website=SynBioBeta|language=en-US}}</ref>

== History ==
Codexis is based in [[Redwood City, CA]] and was incorporated in 2002. It went public in April 2010 on [[NASDAQ]],<ref>{{cite web |last1=Gelsi |first1=Steve |title=Codexis IPO blossoms on Earth Day |url=https://www.marketwatch.com/story/codexis-ipo-blossoms-on-earth-day-2010-04-22 |website=MarketWatch |access-date=10 June 2021}}</ref> and in October, acquired [[Maxygen]]'s MolecularBreeding technology portfolio.<ref>{{cite web |title=License Agreement - Maxygen, Inc. |url=https://www.sec.gov/Archives/edgar/data/1200375/000119312510076663/dex102a.htm |website=www.sec.gov}}</ref>

=== Pharmaceutical ===
Codexis won the [[Presidential Green Chemistry Challenge Award]] from the [[United States Environmental Protection Agency|U.S. Environmental Protection Agency]] (EPA) in 2006 for its work on a building block of [[Lipitor]].<ref>{{Cite web |url=http://ir.codexis.com/phoenix.zhtml?c=208899&p=irol-newsArticle&ID=1181061 |title = Codexis, Inc.:News Release |archive-url=https://archive.today/20120710005236/http://ir.codexis.com/phoenix.zhtml?c=208899&p=irol-newsArticle&ID=1181061 |archive-date=10 July 2012 |url-status=dead}}</ref> It then won a second time in 2010 for its work with [[Merck & Co.]] on the active ingredient in [[Januvia]].<ref name=":1">{{cite news|url=https://www.reuters.com/article/merck-green-idUSN1727061820100617|title=Greener approach to Januvia cuts costs, ups yield|newspaper=Reuters|date=17 June 2010|publisher=|via=www.reuters.com}}</ref>

=== Nutrition ===
In 2017, the company entered a partnership with [[Tate & Lyle]] to provide research and development for the production of new ingredients.<ref>{{Cite web|last=foodnavigator.com|title=Tate & Lyle announce multiyear partnership with Codexis|url=https://www.foodnavigator.com/Article/2017/04/03/Tate-Lyle-announce-multiyear-partnership-with-Codexis|access-date=2021-05-27|website=foodnavigator.com|language=en-GB}}</ref> That same year, Codexis announced a collaboration with [[Nestle]] to provide enzymes for metabolic disorders.<ref>{{Cite web|last=Mullin|first=Rick|date=2017-11-13|title=BASF readies a medical food product|url=https://cen.acs.org/articles/95/i45/BASF-readies-medical-food-product.html|url-status=live|access-date=2021-05-27|website=Chemical & Engineering News|archive-url=https://web.archive.org/web/20190804234506/https://cen.acs.org/articles/95/i45/BASF-readies-medical-food-product.html |archive-date=2019-08-04 }}</ref>

=== Biotherapeutics ===
In 2017, Codexis developed a recombinant [[phenylalanine ammonia-lyase]] (PAL) enzyme, to act as a substitute [[phenylalanine hydroxylase]] (PAH) enzyme for people who suffer from [[phenylketonuria]].<ref name=":0" /> The enzyme was in-licensed by Nestle Health Sciences.<ref name=":0" />

In 2020, [[Takeda Pharmaceutical Company|Takeda Pharmaceutical]] announced a collaboration with Codexis to research and create gene therapies for rare diseases, including [[lysosomal storage disorders]].<ref>{{Cite web|title=Codexis and Takeda partner on gene therapies for rare diseases|url=https://www.pharmaceutical-technology.com/news/takeda-codexis-gene-therapies-deal/|access-date=2021-06-18|website=www.pharmaceutical-technology.com|language=en-GB}}</ref>

=== Life science ===
In June 2020, they announced a partnership with [[Molecular Assemblies]] to engineer enzymes for [[DNA synthesis]].<ref>{{cite web |title=Codexis, Molecular Assemblies Ink Enzyme Engineering Collaboration Agreement |url=https://www.genomeweb.com/business-news/codexis-molecular-assemblies-ink-enzyme-engineering-collaboration-agreement#.YIxL4ZNKgk8 |website=Genomeweb |access-date=24 June 2021 |language=en |date=2020-06-23}}</ref>

== Technology ==
Codexis uses [[directed evolution]] to develop its enzymes.<ref>{{Cite web|last=says|first=Jerry Jeff|date=2010-10-27|title=Xconomy: Codexis Morphs From Big Science Project Into $100M Business|url=https://xconomy.com/san-francisco/2010/10/27/codexis-morphs-from-big-science-project-into-100m-business/|access-date=2021-05-24|website=Xconomy|language=en}}</ref><ref name=":2">{{Cite web|last=says|first=Jerry Jeff|date=2010-10-27|title=Xconomy: Codexis Morphs From Big Science Project Into $100M Business|url=https://xconomy.com/san-francisco/2010/10/27/codexis-morphs-from-big-science-project-into-100m-business/|access-date=2021-06-02|website=Xconomy|language=en}}</ref> Using this method, scientists genetically engineer genes, then screen the enzymes produced to see if it creates the properties needed for a specific reaction.<ref name=":2" /><ref name=":1" /> Their protein engineering platform, called CodeEvolver, uses [[machine learning]] and high-throughput experimentation to learn [[protein sequence]] changes and their impacts on [[protein function]].<ref name=":0" /><ref>{{cite web |title=Patenting Considerations for Artificial Intelligence in Biotech and Synthetic Biology |url=https://www.jdsupra.com/legalnews/patenting-considerations-for-artificial-93433/ |website=JD Supra |language=en}}</ref>

==References==
{{Reflist|30em}}

==External links==
*{{Official website}}

{{Authority control}}

[[Category:Biotechnology companies of the United States]]
[[Category:Companies listed on the Nasdaq]]
[[Category:2002 establishments in California]]
[[Category:Biotechnology companies established in 2002]]
[[Category:Companies based in Redwood City, California]]

Codexis - Revision history

imported>Augmented Seventh: Reverted 1 edit by 74.194.217.93 (talk): Unsourced leadership change